ReposiTrak Adds 50 New Food and Beverage Suppliers to the Queue for the Rapidly Expanding Food Traceability Network
Retailers drive increased focus on food safety and traceability as 50 new suppliers enter the queue to join the ReposiTrak Traceability Network
SALT LAKE CITY, June 03, 2025--(BUSINESS WIRE)--ReposiTrak (NYSE:TRAK), the world's largest food traceability and regulatory compliance network, leveraging its established inventory management and out-of-stock reduction SaaS platform, is proud to add 50 food and beverage suppliers to the queue of companies joining the ReposiTrak Traceability Network® (RTN). These companies will efficiently exchange intricate, FDA-required Key Data Elements (KDEs) for each Critical Tracking Event (CTE) in their supply chains, with the goal of meeting the growing traceability demands of their retail customers.
Among the 50 new suppliers are many whose customers require traceability for all foods, not only Food Traceability List foods. One is a company known for providing nuts, confections, and nostalgic snacks for more than 80 years. Another, founded more than 150 years ago, has deep roots in the snack food sector with their iconic cookies and crackers. A third began in the early 1970s and has grown into a global leader in specialty coffee, offering a wide range of premium beverages, packaged drinks and coffee products available in retail stores worldwide.
"Suppliers large and small can use ReposiTrak to share traceability data with their retail customers in the exact format those customers require," stated Randy Fields, chairman and CEO of ReposiTrak. "We run every traceability data file through a 500+ point error detection process, to ensure it meets both FDA regulations and the often-stricter requirements of retail partners, removing complexity and reducing the risk of noncompliance."
The ReposiTrak Traceability Network requires no additional hardware or software and the ReposiTrak team assists in making the connections needed under the new regulation. Suppliers can connect to an unlimited number of trading partners and share data for a low, flat fee.
About ReposiTrak
ReposiTrak (NYSE: TRAK) provides retailers, suppliers, food manufacturers and wholesalers with a robust solution suite to help reduce risk and remain in compliance with regulatory requirements, enhance operational controls and increase sales with unrivaled brand protection. Consisting of three product families – food traceability, compliance and risk management and supply chain solutions – ReposiTrak's integrated, cloud-based applications are supported by an unparalleled team of experts. For more information, please visit https://repositrak.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603078379/en/
Contacts
Investor Relations Contact:John Merrill, CFOInvestor-relations@repositrak.com
OrFNK IRRob Fink646.809.4048rob@fnkir.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
The Return Trends At Newmont (NYSE:NEM) Look Promising
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. With that in mind, we've noticed some promising trends at Newmont (NYSE:NEM) so let's look a bit deeper. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. To calculate this metric for Newmont, this is the formula: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.14 = US$7.0b ÷ (US$56b - US$5.4b) (Based on the trailing twelve months to March 2025). So, Newmont has an ROCE of 14%. In absolute terms, that's a satisfactory return, but compared to the Metals and Mining industry average of 9.8% it's much better. View our latest analysis for Newmont Above you can see how the current ROCE for Newmont compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering Newmont for free. Investors would be pleased with what's happening at Newmont. Over the last five years, returns on capital employed have risen substantially to 14%. The amount of capital employed has increased too, by 33%. So we're very much inspired by what we're seeing at Newmont thanks to its ability to profitably reinvest capital. A company that is growing its returns on capital and can consistently reinvest in itself is a highly sought after trait, and that's what Newmont has. Investors may not be impressed by the favorable underlying trends yet because over the last five years the stock has only returned 15% to shareholders. So exploring more about this stock could uncover a good opportunity, if the valuation and other metrics stack up. If you'd like to know more about Newmont, we've spotted 2 warning signs, and 1 of them makes us a bit uncomfortable. While Newmont may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
1 Magnificent Growth Stock to Buy Before It Soars Higher After This Event
Oracle stock gained momentum after its latest quarterly report. The stock seems primed for more upside thanks to rapidly growing demand for Oracle's cloud infrastructure. Oracle is on track to deliver faster earnings growth in the future, which could help the stock sustain its bull run. 10 stocks we like better than Oracle › Oracle (NYSE: ORCL) stock has been in fine form on the market over the past couple of months, gaining 77% from its April 21 52-week low. And it looks like this technology giant is primed for more upside following the release of its latest quarterly report. Oracle reported its fiscal 2025 fourth-quarter results (for the three months ended May 31) on June 11. The market reacted positively, pushing the price higher for reasons that aren't all that surprising. Oracle, which made its name by selling database management software, now benefits from the tremendous demand for its cloud infrastructure services. The company not only delivered better-than-expected numbers, but it also issued solid guidance that points toward an even better year. Let's take a look at Oracle's latest report and why it may be a good idea to buy the stock right away. Oracle ended fiscal 2025 with $57.4 billion in annual revenue, up 9% in constant currency terms. The company expects to deliver at least $67 billion in revenue in fiscal 2026 (a jump of almost 17%). Don't be surprised to see Oracle clock even stronger growth, as only some of the company's artificial intelligence (AI)-related catalysts are baked into the guidance. On the earnings call, Oracle Chief Technology Officer Larry Ellison said that the company's revenue pipeline could be much larger than what it is projected in the earnings report. The cloud giant reported a 41% year-over-year increase in its remaining performance obligations (RPO) in fiscal Q4 to $138 billion. RPO refers to the total value of Oracle's contracts that are yet to be fulfilled at the end of a quarter, and the massive increase in this metric explains why it is expecting a stronger top-line increase this year. CEO Safra Catz projects the company's RPO will more than double in fiscal 2026, outpacing the projected growth in its revenue, which can set the stage for years of strong growth for the company. This massive increase in Oracle's RPO can be attributed to the stunning demand for its cloud infrastructure, which is being used for AI training and inference purposes by customers. According to Ellison, Oracle could be understating its RPO if the $500 billion Stargate AI infrastructure project it is a part of pans out as expected. Oracle is one of the key technology partners and funders of the OpenAI-led venture that's backed by SoftBank and Abu Dhabi-based MGX, and it will "closely collaborate to build and operate" AI infrastructure as a part of this project. Meanwhile, the booming demand for cloud AI infrastructure to train and deploy AI applications in general is going to be a long-term tailwind for Oracle, which is finding it difficult to deploy enough capacity to meet the demand. Ellison told analysts on the earnings call that one of its customers wanted to buy Oracle's entire cloud capacity. Not surprisingly, Oracle is going to build 30 dedicated data centers in fiscal 2026, apart from the existing 29 that it already has. It also plans to increase its MultiCloud data centers, which it operates with other major cloud computing providers such as Amazon, Alphabet's Google, and Microsoft, from the current strength of 23 by building another 47 MultiCloud data centers over the next year. This focus on capacity expansion is the reason why the company is forecasting Oracle Cloud Infrastructure (OCI) revenue to grow at a faster pace of 70% in fiscal 2026, following a 50% jump last year. In all, Oracle could be at the beginning of a terrific growth curve, considering the potential catalysts such as Stargate and the opportunity in the cloud infrastructure-as-a-service (IaaS) market that's expected to generate a whopping $712 billion in revenue by 2032, growing at an annual rate of 21%. Oracle delivered non-GAAP (adjusted) net income of $6.03 per share in fiscal 2025, an increase of 8.5% from the prior year. Investors should note that the company's capital expenses more than tripled during the year to $21.2 billion. Its forecast of $25 billion in capital expenses for fiscal 2026, which points toward a slower increase from last year, explains why analysts expect faster bottom-line growth from Oracle this year, and beyond. Moreover, the company seems on its way to crushing its own long-term expectations. Oracle pointed out last year that it expects to hit $66 billion in revenue in fiscal 2026, but its forecast points toward a bigger jump. Also, Oracle expects its bottom line to grow at an annual pace of more than 20% through fiscal 2029. Oracle could eventually do better than that as the market it is serving is massive and the revenue pipeline it is building is remarkable. All this makes Oracle a top AI stock to buy right now as it is trading at just 31 times forward earnings. That's in line with the Nasdaq-100 index's earnings multiple, suggesting that investors can buy Oracle right now at a very attractive valuation, considering the healthy upside it could deliver in the long run. Before you buy stock in Oracle, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Oracle wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, Microsoft, and Oracle. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. 1 Magnificent Growth Stock to Buy Before It Soars Higher After This Event was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
The average healthcare stock has a yield of just 1.7%. Medtronic's dividend yield is 3.3%. Alexandria Real Estate Equities' yield is 7.4%. 10 stocks we like better than Medtronic › The healthcare sector isn't exactly known for offering huge yields, with Health Care Select Sector SPDR (NYSEMKT: XLV) offering a yield of just 1.7%. If dividend investors take some time to dig into the sector, however, they can do much better. For example, Medtronic (NYSE: MDT) has a 3.3% yield today, and Alexandria Real Estate Equities (NYSE: ARE) is offering a yield of 7.4%. Here's what you need to know about each of these high-yield healthcare stocks. Medtronic makes medical devices. It is one of the largest competitors in the space, making products across the cardiovascular, neuroscience, medical surgical, and diabetes categories. It has a leading position in each of the areas in which it operates, and it operates on a global scale. That said, the last few years haven't been the best ones for the company. Innovation, which is highly important in the healthcare space, can be lumpy. And given Medtronic's size, the business has become a little cumbersome. Growth has stalled out, and profitability has come under pressure. Investors have focused on the negatives pushing the shares lower and the dividend yield up toward the high end of Medtronic's historical yield range. If you are a dividend investor that thinks in decades and not days, however, this is likely to be an investment opportunity. The company's innovation pipeline is starting to turn into new-product introductions. As new products gain traction, financial performance is likely to improve. And management has been working to streamline the business with cost cuts and a move to refocus on its most profitable operations. To that end, the company is set to spin off its lower-margin diabetes division in 2026. The move is expected to be immediately accretive to earnings, and the dividend policy isn't expected to change. All in, Medtronic is doing what it needs to do to get back on the growth path. And that should support continued dividend increases; the medical device maker only has two years to go before it hits Dividend King status (50+ years of annual dividend increases). June could be an opportune time to buy the stock hand over fist. Alexandria is a real estate investment trust (REIT), which seems pretty far away from healthcare. Its primary focus is on office properties, which also seems a bit removed from healthcare. The key here is that the REIT owns biomedical research facilities, which combine research space and office space in one property. Both are important to each other since the research takes place in specialized space, while the analysis of that research takes place in a normal office environment. Alexandria is one of the largest pure play medical research REITs you can buy. Alexandria counts some of the largest and most important medical research groups as tenants, from both the private side of the equation and the government side. However, like any landlord, the REIT's revenues will be impacted by the occupancy levels of its properties. And those rise and fall over time. Right now, occupancy is relatively weak, dropping to 91.7% at the end of the first quarter of 2025 from 94.6% at the end of 2024. Swings like this happen from time to time, but Wall Street is treating Alexandria as if its dividend is at a material risk of being cut. Only the funds from operations (FFO) payout ratio in the first quarter was a fairly strong 57%. There's room for adversity before a dividend cut would be in order. To be fair, office properties, and particularly highly specialized office properties, tend to have higher operating costs than other real estate assets. But it seems highly likely that Alexandria will manage its way through this weak patch and continue to extend its 15-year streak of annual dividend increases. For income lovers, this healthcare REIT is worth a deep dive in June. The average healthcare stock has an uninspiring dividend yield. But the average is made up of many different companies, some of which actually have very attractive dividend yields. That list includes industry-leading companies like Medtronic and Alexandria Real Estate. You might just want to pick up shares in one, or both, of these high yielders before June is over after you get to know them a little better. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Alexandria Real Estate Equities. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. 2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
